News | December 11, 2013

Compañía Mexicana de Radiología Acquires Naviscan Assets

CMR Naviscan Exhibits at RSNA 2013

December 11, 2013 — Compañía Mexicana de Radiología, CGR, S.A. de C.V. (CMR) acquired certain Naviscan Inc. assets, including intellectual property and the Naviscan trademark.  CMR plans to continue sales and support of Naviscan’s high-resolution organ-specific positron emission tomography (PET) imaging technology.
 
CMR, a Mexico-based company, has been a developer and manufacturer of quality diagnostic imaging equipment and healthcare IT solutions for more than 25 years. CMR recently established a U.S.-based corporation — CMR Naviscan Corp. — that will continue to develop and manufacture Naviscan’s molecular imaging technology in Carlsbad, Calif.
 
“In addition to sustaining this critical technology for breast cancer patients, we will be able to provide a more comprehensive product offering to our healthcare customers,” said Tonatiuh Monroy, director general, CMR. “We are committed to retaining the high level of product quality and customer service established by Naviscan.”
 
The new company exhibited its products at the Radiological Society of North America Annual Meeting (RSNA 2013) in Chicago.
 
For more information: www.cmr-naviscan.com, www.rsna.org

Related Content

News | Business | September 19, 2017
September 19, 2017 — Invicro LLC, a provider of imaging services and software for research and drug development, anno
ScImage and Invia Partnership Announced
News | PACS | September 19, 2017
ScImage Inc. and Invia Imaging Solutions recently announced formation of a joint partnership at the American Society of...
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Philips Launches CardioMD IV Cardiac SPECT Solution at ASNC 2017
Technology | SPECT Imaging | September 15, 2017
September 15, 2017 — Philips highlighted its newest solution for...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
German Team Optimizing Therapy Planning for Cancers of the Liver
News | Interventional Radiology | August 29, 2017
Radioembolization is a therapy method used for liver tumors that are uncurable with surgery or chemotherapy. Thorough...
Sponsored Content | Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
Overlay Init